Introduction
Comprehensive basic research has considerably enlarged our knowledge about the biological and biochemical mechanism of erectile function and erectile dysfunction (ED), focusing the interest of both physician and pharmaceutical industry on new attractive target enzymes and ion channels. 1 In this context, it has been proven that the nitric oxideguanylylcyclase-cyclic guanosine monophosphate (cGMP)-phosphodiesterase pathway is of utmost interest in the development of new compounds that attack the generation or cleavage of cGMP. 2 These general considerations are supported by the success of sildenafil, the first oral phosphodiesterase 5 (PDE-5) inhibitor in the management of ED. 3 Tadalafil represents a new compound of the PDE-5 inhibitor class, which has proven to have a clearly higher potency to the PDE-5 enzyme than sildenafil. 4, 5 Integrated analyses of data from five phase III trials demonstrated that tadalafil, at doses from 5 to 20 mg, significantly improved erectile function (versus placebo) by all efficacy measures. [6] [7] [8] Another important characteristic of tadalafil is its prolonged period of responsiveness (at least 24 h after dosing). 9 Besides, food did not alter the rate and extent of absorption of this drug. 10 These characteristics should release couples from the need to plan sexual activities and therefore provide the highest amount of spontaneity for sexual activity. The aim of our study is to evaluate the chronological distribution of sexual intercourses in a group of patients treated with tadalafil versus placebo for 3 months.
Materials and methods
Between September and November 2003 we selected 134 patients with erectile dysfunction visited consecutively at our outpatients' department.
All the patients signed an informed consent and underwent three visits during the study: Visit 0, when we diagnosed erectile dysfunction; Visit 1, 1 month after, when we made the randomization; Visit 2, 3 month after Visit 1, when we have collected data.
Men who had a minimum 3-months history of erectile dysfunction, with a steady female partner, were included in our study while we excluded from the study patients who failed to achieve erection following pelvic surgery, or had clinically significant penile deformities or penile implants, a recent history of stroke (within 6 months) or spinal cord trauma, and/or clinically significant renal or hepatic insufficiency. Men treated with nitrates, antiandrogens or cancer chemotherapy were also excluded from the study.
At the screening visit (Visit 0), a medical history, physical examination and laboratory safety test, including an electrocardiogram, were performed.
Among the 134 patients, nine treated with nitrates and five with hepatic insufficiency have been excluded from the study. The remaining 120 patients received the Sexual Encounter Profile (SEP) 13 diary to record each sexual attempt throughout the study and spent a 4-week treatment-free runin-period during which they recorded the SEP diary.
At Visit 1 patients filled in the International Index of Erectile Function (IIEF) 11, 12 and were randomized in two groups of 60 patients. The first group of patients has been treated with tadalafil 20 mg, while the other group with placebo. The baseline characteristics were well balanced in the two treatment groups (Table 1) .
Randomization was performed using 120 opaque envelopes, 60 containing study protocol with tadalafil and another set of 60 containing study protocol with placebo. The 120 envelopes were sealed, mixed and numbered in progressive order before being placed in a box. Each patient, following the order of his examination, was given an envelope with the treatment he had to follow. All the patients of the two groups were requested to take one pill of tadalafil/placebo on Tuesday and on Friday and to engage in sexual activities whenever they were in the mood, with no restriction of food or alcohol intake, after 30 min from drug assumption and up to the next pill assumption for 3 months.
Besides, they were requested to make at least four attempts a month. After 3 months of therapy patients underwent Visit 2 to control SEP diary and to fill in IIEF another time.
The mean change from baseline to end point on the erectile function domain of the IIEF (particularly IIEF 1-5 and 15) and the absolute proportion of affirmative responses to the five questions in the SEP diary constituted primary efficacy outcome measures. 13 Unpaired t-test has been used to evaluate changes of IIEF score and changes in proportions of responses to the SEP diary, treated as continuous outcomes. The study was a spontaneous and not a financed trial.
Results
A total of 134 patients started the study but 14 were excluded at the screening visit (Visit 0) because they were not eligible. One patient of the tadalafil group and two patients of the placebo group were discontinued because of protocol violation. The remaining 117 patients completed the study.
After 3 months of therapy, at Visit 2, the mean IIEF erectile function domain score increased significantly from baseline to end point of 12 points (Po0.01) in the tadalafil group while the increase was not significant in the placebo group (2.9 points) ( Table 2) .
Likewise, mean changes from baseline to end point in proportions of sexual attempts marked by erection (SEP-Q1), successful penetration (SEP-Q2), intercourse completion (SEP-Q3), satisfaction of hardness of erection (SEP-Q4) and sexual experience (SEP-Q5) were significantly increased in the tadalafil group (Po0.01) while these were not significant in the placebo group (Table 2) .
In the tadalafil group, eight patients (14%) reported their first successful intercourse between 30 and 60 min after dosing; 22 patients (41%) between 1 and 6 h; 13 patients (24%) between 6 In the placebo group, two patients (3%) reported the first successful intercourse between 30 and 60 min after dosing; four patients (7%) between 1 and 6 h; 52 (90%) patients did not report successful intercourses (Figure 1) .
If we consider all the 3 months of assumption period, in the tadalafil group, between the 43 patients (79%) that have reported successful intercourses, 8% of successful sexual attempts have been recorded between 30 and 60 min, 12% between 1 and 6 h; 35% between 6 and 12 h; 28% between 12 and 24 h; 10% between 24 and 36 h; 5% between 36 and 48 h and 2% between 48 and 60 h.
In the placebo group, between the six patients, 22% of successful sexual attempts were reported between 30 and 60 min, 22% between 1 and 6 h and 56% between 6 and 12 h (Figure 2 ). Besides, in the tadalafil group, 46 patients (78%) reported the recovery of erections during the night, at the awakening and during the day after simple caresses or kisses, not followed by the complete sexual relationship, for obvious social context impossibility. Nine patients (16%) of the placebo group reported these events.
Safety results: Tadalafil was well tolerated. Six patients reported headache while four patients flushing and two patients dyspepsia. These events were mostly mild or moderate and decreased in frequency with continued treatment. Two patients reported myalgia and back pain treated with antiinflammatory drugs. In the placebo group, three patients reported headache while two patients reported dyspepsia. None of the patients from both groups abandoned the study due to adverse events.
Comment
Tadalafil is a new, potent and reversible inhibitor of phosphodiesterase type 5. [4] [5] [6] In randomized controlled studies, therapy with tadalafil at doses of 2.5-20 mg significantly improved erectile function. 7, 8 Brock et al 9 report that, at doses of 10 and 20 mg, 40 and 59% of patients, respectively, had returned to have a normal erectile function as compared with placebo-treated patients. On the basis of our data, tadalafil has confirmed its efficacy with a significant increase of IIEF and success SEP diaries in the group treated with tadalafil (Po0.01) versus the placebo group. We have recorded a significant improvement in tadalafil group about erection (SEP-Question 1), successful penetration (SEP-Question 2), intercourse completion (SEP-Question 3), satisfaction of hardness of erection (SEP-Question 4) and sexual experience (SEP-Question 5). Particularly, with regard to SEP-Question 5, 81% of patients treated Sexual activity in patients treated with tadalafil AF De Rose et al with tadalafil were satisfied by their sexual experience versus 10% of the placebo group. With regard to the chronological distribution of sexual intercourses, in tadalafil group, between the 43 patients that have reported successful intercourses, a wide percentage of them (41%) reported the first successful intercourse between 1 and 6 h, but most successful intercourses have been reported between 6 and 12 h (35%) and between 12 and 24 h (28%). Even in the placebo group, between the six patients that have reported successful intercourses, the main percentage of sexual activities has been recorded between 6 and 12 h.
These data could be related to the same counselling of tadalafil/placebo assumption given to the two groups of patients, and probably these results can be due to the low mean age of patients (46 y). This chronological distribution of sexual intercourses in the two groups seems to suggest that the patients, after a first period in which they want to verify the efficacy of the drug, choose to have sexual intercourses at periods far from the pill intake so that they do not correlate the pill intake to sexual activity. Besides, a percentage of patients in tadalafil group reported satisfied intercourses over 24 h up to 60 h (10, 5, 2% of successful intercourses in the period between 24 and 36, 36 and 48 and 48 and 60 h, respectively). Not one patient of the placebo group has reported sexual intercourses over 16 h. Brock et al reported that, at a dose of 20 mg, tadalafil enabled up to 80% of sexual intercourse attempts to be completed succesfully between 30 min and 36 h after dosing. 8 As already mentioned by other authors, also in our study, tadalafil has exhibited a broad window of therapeutic responsiveness. [14] [15] [16] Another important aspect is the rate of spontaneous erections (78%) reported during the study at night, at awakening and all day long after simple caresses or kisses in the group treated with tadalafil. These aspects could improve patient spontaneity during sexual activities. Our data accord with those reported in a recent study written by Jannini et al, 17 who have defined phosphodiesterase inhibitors as 'harmonious drugs' and tadalafil as the 'most harmonious therapy for erectile dysfunction'. In fact, the long half-life and the rate of spontaneous erections after tadalafil intake seem to improve people's sexuality besides the quality of sexual intercourses.
Conclusions
The efficacy of tadalafil, its long half-life and the high rate of spontaneous erections probably contributed to reassure patients, leading them to engage in sexual intercourses many hours after pill assumption and regain their sexual spontaneity.
